Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies
Daniel Rönen, Aseel Bsoul, Michal Lotem, et al.
Vaccines (2022) Vol. 10, Iss. 4, pp. 540-540
Open Access | Times Cited: 18

Showing 18 citing articles:

Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors
Layla Shojaie, Jacob Bogdanov, Helia Alavifard, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 2
Open Access | Times Cited: 9
Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
Laura I. Yousif, Elles M. Screever, Daniëlle Versluis, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 7, pp. 753-763
Open Access | Times Cited: 16
Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review
Dong Wang, Johann Bauersachs, Dominik Berliner
Biology (2023) Vol. 12, Iss. 3, pp. 472-472
Open Access | Times Cited: 14
Association between Immune Checkpoint Inhibitors and Atherosclerotic Cardiovascular Disease Risk: Another Brick in the Wall
Linda Piras, Michela Zuccanti, Paola Russo, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2502-2502
Open Access | Times Cited: 4
The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure
Song Huang, Yu Kang, Ting Liu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
ICIs-Related Cardiotoxicity in Different Types of Cancer
Mei Dong, Ting Yu, Zhenzhen Zhang, et al.
Journal of Cardiovascular Development and Disease (2022) Vol. 9, Iss. 7, pp. 203-203
Open Access | Times Cited: 18
The role of immune checkpoints in cardiovascular disease
Laura I. Yousif, Anniek A. Tanja, Rudolf A. de Boer, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 17
Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings—A Case Report and Literature Review
Elena Giovannini, Maria Paola Bonasoni, Michele D’Aleo, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10919-10919
Open Access | Times Cited: 10
Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC)
Adila Abulizi, Guang-Peng Yan, Qian Xu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Blocking CTLA‐4 promotes pressure overload‐induced heart failure via activating Th17 cells
An‐Qi Shang, Changjiang Yu, Xin Bi, et al.
The FASEB Journal (2024) Vol. 38, Iss. 15
Closed Access | Times Cited: 2
Insight of immune checkpoint inhibitor related myocarditis
Jin-Kui Pi, Xiao-Ting Chen, Yanjing Zhang, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113559-113559
Closed Access | Times Cited: 2
The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database
Huaju Yang, Zheran Liu, Ruidan Li, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
Myositis associated with pembrolizumab presenting with myastheniform symptoms: two case reports
S. Deveci, Mustafa Uzun, Pınar Özçelik, et al.
Anti-Cancer Drugs (2024)
Closed Access | Times Cited: 1
The Good (Tumor Killing) and the Bad (Cardiovascular Complications) of Immunologic Checkpoint Inhibitors
María T. Gamero, Amar Patel, Eugene Storozynsky
Current Cardiology Reports (2024)
Open Access | Times Cited: 1
Pathogenesis, Diagnosis and Treatment of Immune-Related Cardiotoxicity
静宜 任
Advances in Clinical Medicine (2024) Vol. 14, Iss. 03, pp. 284-290
Closed Access
Cardiovascular Adverse Events and Immune-related Adverse Events Associated with PD-1/PD-L1 Inhibitors for Head and Neck Squamous Cell Carcinoma (HNSCC): A Real-world study (RWS) by Bayesian Disproportional Analysis Based on the FDA Adverse Event Reporting System (FAERS)
Adila Abulizi, Guang-Peng Yan, Qian Xu, et al.
Research Square (Research Square) (2024)
Open Access
The Stroma and Tumor Microenvironment Are Not the Most Instrumental Players in Tumor Cells Immune Evasion, Growth, and Resistance to Therapy
Hatem Tallima, Rashika El Ridi
(2022)
Open Access | Times Cited: 1
Aspirin use increases risk of immune-related adverse events in cancer patients treated with immunotherapy: analysis of the FAERS database
huaju yang, Zheran Liu, Ruidan Li, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top